Welcome to AntoXa Corporation’s newsroom.
For media inquiries, please contact:
Stacey Curry Gunn
Director of Communications
[email protected]
519.827.1131
See below for links to the latest AntoXa news.
AntoXa Corporation and SwiftPharma Sign Exclusive Collaboration Agreement to Support the Development and Commercialization of a Plant-Made Antibody Against Ricin Exposure
GHENT, Belgium and TORONTO, Canada, September 5, 2023 – AntoXa Corporation, a Canadian biopharmaceutical company developing medical countermeasures against biological and chemical agents that might be used in terrorist attacks, and SwiftPharma, a leading innovator in the research & development of recombinant proteins derived from a proprietary plant-based production system, ...
U.S. Patent Granted for Made-in-Canada Ricin Antibody Technology
GUELPH, Ont., CANADA, Feb. 27, 2023 — The U.S. Patent Office has granted a patent for a plant-based manufacturing process to produce an antibody for treatment of ricin exposure, an outcome of research and development by AntoXa Corporation under contract with Defence Research & Development Canada (DRDC), an Agency of ...
AntoXa Corporation awarded contract extension with federal government to develop plant-made protein for potential coronavirus therapy
DRDC-funded project aims to develop recombinant human angiotensin-converting enzyme 2 (ACE2) as a potential drug candidate for COVID-19 GUELPH, Ontario, Canada, August 17, 2021 — Canadian biopharmaceutical company AntoXa Corporation has been awarded a contract extension from the Government of Canada that includes development of plant-made recombinant human angiotensin-converting enzyme ...
AntoXa awarded federal government contract for anti-nerve agent enzyme
GUELPH, Ontario, Canada, March 20, 2019 — AntoXa Corporation has been awarded a contract with the Government of Canada to continue work on production of plant-made butyrylcholinesterase (BuChE), a protein that provides protection against toxic nerve agents such as sarin and soman. The one-year contract, worth up to $329,395, with ...
Ashley J. Meyers appointed President and COO of AntoXa Corporation
Guelph, Ont., Canada, Dec. 20, 2018 — AntoXa Corporation announced today that Ms. Ashley J. Meyers has been appointed President and Chief Operating Officer (COO). Ashley J. Meyers, President and COO of AntoXa Corporation. Ms. Meyers has been a member of the Canadian biopharmaceutical company’s leadership team since the company’s ...
